Is Addex Therapeutics Stock a Good Investment?
Addex Therapeutics Investment Advice | ADXN |
- Examine Addex Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Addex Therapeutics' leadership team and their track record. Good management can help Addex Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Addex Therapeutics' business and its evolving consumer preferences.
- Compare Addex Therapeutics' performance and market position to its competitors. Analyze how Addex Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Addex Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Addex Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Addex Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Addex Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Addex Therapeutics Stock
Researching Addex Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 0.75. Some equities with similar Price to Book (P/B) outperform the market in the long run. Addex Therapeutics recorded a loss per share of 21.6. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 23rd of October 2023.
To determine if Addex Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Addex Therapeutics' research are outlined below:
| Addex Therapeutics generated a negative expected return over the last 90 days | |
| Addex Therapeutics has high historical volatility and very poor performance | |
| Addex Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.61 M. Net Loss for the year was (10.56 M) with profit before overhead, payroll, taxes, and interest of 1.44 M. | |
| Addex Therapeutics currently holds about 8.81 M in cash with (7.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4. | |
| Addex Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Marketscreener.com |
Addex Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Addex Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Addex Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Addex Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Addex Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-04 | 2021-09-30 | -0.8527 | -0.723 | 0.1297 | 15 | ||
2021-05-05 | 2021-03-31 | -0.6565 | -0.5256 | 0.1309 | 19 | ||
2021-08-05 | 2021-06-30 | -0.7876 | -0.9263 | -0.1387 | 17 | ||
2022-03-10 | 2021-12-31 | -0.6492 | -0.8151 | -0.1659 | 25 | ||
2023-05-11 | 2023-03-31 | -0.0516 | -0.2684 | -0.2168 | 420 | ||
2022-05-05 | 2022-03-31 | -0.5163 | -0.9136 | -0.3973 | 76 | ||
2022-08-18 | 2022-06-30 | -0.1353 | -1.19 | -1.0547 | 779 | ||
2023-03-30 | 2022-12-31 | -0.0516 | -1.38 | -1.3284 | 2574 |
Know Addex Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Addex Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Addex Therapeutics backward and forwards among themselves. Addex Therapeutics' institutional investor refers to the entity that pools money to purchase Addex Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 3 K | Adar1 Capital Management Llc | 2024-09-30 | 1000 |
Addex Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.38 M.Market Cap |
|
Addex Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.27) | (2.16) | |
| Return On Capital Employed | (5.90) | (5.60) | |
| Return On Assets | (2.27) | (2.16) | |
| Return On Equity | (9.22) | (8.75) |
Determining Addex Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Addex Therapeutics is a good buy. For example, gross profit margin measures Addex Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Addex Therapeutics' profitability and make more informed investment decisions.
Evaluate Addex Therapeutics' management efficiency
Addex Therapeutics has return on total asset (ROA) of (0.6171) % which means that it has lost $0.6171 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2629) %, meaning that it created substantial loss on money invested by shareholders. Addex Therapeutics' management efficiency ratios could be used to measure how well Addex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to grow to -2.16. In addition to that, Return On Capital Employed is likely to grow to -5.6. At this time, Addex Therapeutics' Intangible Assets are very stable compared to the past year. As of the 27th of November 2024, Other Assets is likely to grow to about 66 K, while Total Assets are likely to drop about 4.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.02 | 0.01 | |
| Tangible Book Value Per Share | 0.02 | 0.01 | |
| Enterprise Value Over EBITDA | 0.01 | 0.01 | |
| Price Book Value Ratio | 2.98 | 2.83 | |
| Enterprise Value Multiple | 0.01 | 0.01 | |
| Price Fair Value | 2.98 | 2.83 | |
| Enterprise Value | -103 K | -97.8 K |
The management strategies employed by Addex Therapeutics' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta 1.874 |
Basic technical analysis of Addex Stock
As of the 27th of November, Addex Therapeutics shows the mean deviation of 4.61, and Risk Adjusted Performance of 0.0549. Addex Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Addex Therapeutics' Outstanding Corporate Bonds
Addex Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Addex Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Addex bonds can be classified according to their maturity, which is the date when Addex Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Understand Addex Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Addex Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0549 | |||
| Market Risk Adjusted Performance | 0.4897 | |||
| Mean Deviation | 4.61 | |||
| Semi Deviation | 4.96 | |||
| Downside Deviation | 5.38 | |||
| Coefficient Of Variation | 1666.12 | |||
| Standard Deviation | 8.18 | |||
| Variance | 66.85 | |||
| Information Ratio | 0.0441 | |||
| Jensen Alpha | 0.36 | |||
| Total Risk Alpha | (0.81) | |||
| Sortino Ratio | 0.067 | |||
| Treynor Ratio | 0.4797 | |||
| Maximum Drawdown | 69.82 | |||
| Value At Risk | (7.40) | |||
| Potential Upside | 9.89 | |||
| Downside Variance | 28.89 | |||
| Semi Variance | 24.6 | |||
| Expected Short fall | (5.56) | |||
| Skewness | 3.59 | |||
| Kurtosis | 22.59 |
| Risk Adjusted Performance | 0.0549 | |||
| Market Risk Adjusted Performance | 0.4897 | |||
| Mean Deviation | 4.61 | |||
| Semi Deviation | 4.96 | |||
| Downside Deviation | 5.38 | |||
| Coefficient Of Variation | 1666.12 | |||
| Standard Deviation | 8.18 | |||
| Variance | 66.85 | |||
| Information Ratio | 0.0441 | |||
| Jensen Alpha | 0.36 | |||
| Total Risk Alpha | (0.81) | |||
| Sortino Ratio | 0.067 | |||
| Treynor Ratio | 0.4797 | |||
| Maximum Drawdown | 69.82 | |||
| Value At Risk | (7.40) | |||
| Potential Upside | 9.89 | |||
| Downside Variance | 28.89 | |||
| Semi Variance | 24.6 | |||
| Expected Short fall | (5.56) | |||
| Skewness | 3.59 | |||
| Kurtosis | 22.59 |
Consider Addex Therapeutics' intraday indicators
Addex Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Addex Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Addex Therapeutics Corporate Filings
6K | 22nd of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
F3 | 14th of August 2024 An amendment to the original Schedule 13D filing | ViewVerify |
| 24th of April 2024 Other Reports | ViewVerify |
Addex Stock media impact
Far too much social signal, news, headlines, and media speculation about Addex Therapeutics that are available to investors today. That information is available publicly through Addex media outlets and privately through word of mouth or via Addex internal channels. However, regardless of the origin, that massive amount of Addex data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Addex Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Addex Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Addex Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Addex Therapeutics alpha.
Addex Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Addex Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Addex Therapeutics Corporate Management
| Timothy Dyer | CEO CoFounder | Profile | |
| Werner Henrichi | Consultant | Profile | |
| Mikhail Kalinichev | Head Science | Profile | |
| JeanPhilippe Rocher | Head Chemistry | Profile | |
| Roger MD | Chief Director | Profile | |
| Lnaic Teyssdou | Head Finance | Profile | |
| Robert Lutjens | Head Biology | Profile |
Already Invested in Addex Therapeutics?
The danger of trading Addex Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Addex Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Addex Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Addex Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (21.60) | Revenue Per Share 1.2 | Quarterly Revenue Growth (0.82) | Return On Assets (0.62) | Return On Equity (1.26) |
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Addex Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.